Lower Urinary Tract Symptoms Clinical Trial
Official title:
Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for Diagnosis and Management of Bladder Outlet Obstruction in Men
Background and study aims: The prostate gland sits around the exit of the bladder in men. As
men get older, the prostate grows, and this can narrow the exit from the bladder, so that
there is restriction of flow. As a result, some men develop difficulty passing urine
(voiding) as they age. For these men, prostate surgery can be helpful by removing the part of
the prostate causing the narrowing, so that flow improves. However, for some men, almost
identical symptoms of difficulty passing urine are due to underactive bladder. In other
words, the bladder contraction is too weak, and is not effective at expelling the urine. This
is a smaller group, but important, as these men may have no improvement after prostate
surgery, while being exposed to risk of complications of surgery. Medical assessment of men
with voiding problems typically involves discussing the symptoms, doing a physical
examination of the prostate and measuring the urine flow rate. In many NHS hospitals, these
are the only tests done before deciding whether to proceed to prostate surgery. In effect,
voiding symptoms are presumed to be a result of prostate enlargement for these men, since it
is the more common problem compared with bladder underactivity. However, this approach cannot
identify which men actually have bladder underactivity as the cause of their voiding
symptoms. So, in some hospitals an extra test is used, called urodynamics. Urodynamics is
done to measure how much pressure the bladder generates when passing urine, because a high
pressure shows the problem is obstruction, and a low pressure shows it is bladder weakness.
Urodynamics involves gently putting a small tube into the bladder via the penis to measure
the bladder pressure, and to fill the bladder with a sterile fluid (saline). Another small
tube is gently placed into the rectum, via the anus, to measure abdominal pressures.
Measuring abdominal pressure is necessary because any change in abdominal pressure can affect
bladder pressure, and if the test did not allow for this it could give a misleading result.
Urodynamics is safe, but some men find it uncomfortable or undignified, and a few develop
urine infection afterwards. No studies have been conducted so far to tell us which of these
two approaches to assessing men with voiding urinary problems is better overall.
UPSTREAM consists of two phases: "UPSTREAM - Phase I" was a pragmatic, two-arm, multicentre,
randomised controlled trial (RCT) to determine the clinical and cost-effectiveness of
invasive urodynamics (UDS) for the diagnosis and management of bladder outlet obstruction in
men. Men from 26 urology departments of NHS Hospitals in England who had bothersome lower
urinary tract symptoms (LUTS) and were seeking further treatment, which may have included
surgery, were randomised to one of two study arms; 'Routine Care' (as per the NICE diagnostic
pathway), or routine care plus UDS ('Urodynamics'), which is currently optional. The design
was utilised to establish noninferiority in symptom severity (International Prostate Symptom
Score [IPSS]) 18-months post-randomisation. The primary outcome was IPSS at 18-months
post-randomisation, and a key secondary outcome was the influence of UDS on rates of bladder
outlet surgery. The RCT started 01 April 2014 and ended 30 September 2018.
In 2018, we were awarded an extension to conduct a further (long term) follow up of UPSTREAM
participants, five years post-randomisation; "UPSTREAM - Phase II". We aim to identify: the
symptom outcomes of treatment; definitive surgery rates in the two study arms; and the
long-term impact of LUTS and its therapy. The focus will continue to be on effectiveness and
patient outcomes as per the original commissioning brief. "UPSTREAM - Phase II" started 01
July 2019 and has a planned end date of 30 June 2022.
The aim of the UPSTREAM trial ("UPSTREAM - Phase I") was to determine whether a care pathway
including invasive urodynamics is no worse for men in terms of symptom outcome than one in
which it is not included, at 18 months after randomisation. We also aimed to establish
whether inclusion of invasive urodynamics reduces rates of bladder outlet surgery as a main
secondary outcome.
The following men were invited to participate (inclusion criterion); • Men seeking further
treatment for their bothersome lower urinary tract symptoms (LUTS) which may include surgery
Men were not invited to participate (exclusion criteria) if they:
- were unable to pass urine without a catheter (urinary retention)
- had a relevant neurological disease, such as a stroke
- were undergoing treatment for prostate or bladder cancer
- had previously had prostate surgery
- were not medically fit for surgery, or were unable to complete outcome assessments
- did not consent to be assigned at random to one of the pathways
We compared the two methods of investigation by finding out whether the men had similar
relief of their symptoms, by measuring the change in the prostate symptom score (IPSS) in the
two groups at 18 months after randomisation (primary outcome).
We also looked at the following secondary outcomes:
- Whether the invasive tests changed the decision for surgery in some of the men (how many
men had surgery in each of the two groups?)
- The cost-effectiveness of the two management pathways
- Adverse effects of (a) the tests and (b) the treatments (e.g. urinary infection, urinary
retention)
- Urinary symptoms at 6, 12 & 18 months, using the International Consultation on
Incontinence Questionnaires (ICIQ) and the Male Lower Urinary Tract Symptoms
questionnaire (ICIQ-MLUTS)
- Quality of life, using the IPSS-QoL question
- Sexual function, using the ICIQ-MLUTS sex questionnaire
- Satisfaction with urodynamic testing, using the ICIQ-UDS-S questionnaire
- The maximum urinary flow rate (Qmax) at 18 months
- Health outcomes, using the EQ-5D-5L questionnaire
For "UPSTREAM - Phase II". In this further follow up study ("UPSTREAM - Phase II"), we want
to find out the longer term (5-year) results of treatment for the men's LUTS, and see how
many men went on to receive surgery after the initial 18-months (i.e. after the original
study, "UPSTREAM - Phase I").
We will approach existing participants of the UPSTREAM trial ("UPSTREAM - Phase I"). In
taking part in "UPSTREAM - Phase II", men do not need to return to hospital for any clinical
assessments. Instead we will ask them to complete one questionnaire booklet about their
urinary symptoms, the effect on their everyday life, and their general state of health. We
will also securely collect information relevant to this study from central NHS records (such
as information about relevant inpatient stays and outpatient attendances).
Outcome measures will include:
LUTS will be measured with the widely-used patient reported outcome, the International
Prostate Symptom Score (IPSS), at five years post-randomisation.
• Measures from the International Consultation on Incontinence Questionnaires (ICIQ) will
also be used, giving sensitive and comprehensive assessment of LUTS severity/ bother, sexual
function and quality of life (QoL), i.e.: O IPSS QoL O ICIQ Male LUTS (ICIQ-MLUTS) O ICIQ
sexual function in Male LUTS (ICIQ-MLUTS-sex)
- The EQ-5D-5L will be used to provide the QoL weights used to calculate Quality Adjusted
Life Years (QALYs).
- Data for: Surgery rates (the relative proportion of men in each group having surgery up
to five years post-randomisation); diagnostic testing after the main trial (where
possible); and resource use will be obtained via a one-off bespoke data extraction of
Health Episode Statistics (HES) and HES-Office of National Statistics (ONS) linked data,
via NHS Digital. This will include individual level data about participants' relevant:
inpatient stays; outpatient attendances: including procedures; radiology and accident
and emergency (A&E) episodes; and cause of death (where applicable).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT03623880 -
Enhancing Behavioral Treatment for Women With Pelvic Floor Disorders
|
N/A | |
Enrolling by invitation |
NCT06317116 -
Examining the Relationship Between Core Muscles and Bladder Issues in Children
|
||
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Recruiting |
NCT05814614 -
Bladder Complaints in Parkinson's Disease Effectiveness of Pelvic Floor Muscle Exercises and Electrical Stimulation
|
N/A | |
Recruiting |
NCT04288427 -
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
|
N/A | |
Not yet recruiting |
NCT06452927 -
EEP in Patients With Urodynamically Proven DU/DA
|
N/A | |
Completed |
NCT03339609 -
Uroflow Measurement With Electromyography (EMG) to Identify Lower Urinary Tract Symptoms (LUTS): Conducted on Healthy Children
|
N/A | |
Completed |
NCT02330107 -
Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men
|
N/A | |
Terminated |
NCT02003742 -
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
|
Phase 3 | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT01078545 -
Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)
|
N/A | |
Completed |
NCT02074644 -
Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia
|
N/A | |
Recruiting |
NCT03802851 -
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT05415748 -
Deprescribing Tamsulosin in Older Men
|
Phase 4 | |
Recruiting |
NCT05702294 -
Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries .
|
N/A | |
Enrolling by invitation |
NCT05537272 -
The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy
|
Phase 4 | |
Recruiting |
NCT05826691 -
Benign Prostate Surgery and QOL and Sexual Function
|
||
Completed |
NCT04104100 -
Prevalence and Risk Factor of NP in Women With LUTS
|
||
Completed |
NCT04190641 -
Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder
|
N/A |